Contrave vs Phentermine 2026: Which Non-GLP-1 Weight Loss Drug Is Better?

Contrave and Phentermine: Two Non-GLP-1 Weight Loss Approaches

Contrave (naltrexone/bupropion extended-release) and phentermine are the two most commonly prescribed non-GLP-1 weight loss medications in the US, and they are meaningfully different in mechanism, duration, and side effect profile. Understanding these differences helps patients decide between them — and whether either is appropriate versus a GLP-1 option through the Tmates platform's weight loss category.

Phentermine (available through Tmates at $149/mo) works through norepinephrine release in the CNS — rapid-onset appetite suppression with increased energy. It is approved only for short-term use (typically ≤12 weeks) and is a Schedule IV controlled substance due to its stimulant properties. Most patients see rapid results in weeks 1–4, with efficacy tapering as tolerance develops. Average weight loss: 3–7% in 12-week courses.

Contrave combines naltrexone (an opioid antagonist used for addiction) with bupropion (an antidepressant also used for smoking cessation). Together they modulate reward pathways in the brain — reducing the hedonic drive to eat rather than producing the stimulant appetite suppression of phentermine. Contrave is approved for long-term use (unlike phentermine) and produces 4.8–5.0% average weight loss over 56 weeks in clinical trials — marginally better than phentermine over a similar timeframe but approved for longer continuous use.

Neither Contrave nor phentermine produces results approaching semaglutide (14.9%) or tirzepatide (22.5%) in head-to-head clinical comparisons. If the primary goal is significant, sustained weight loss, semaglutide at $249/mo or tirzepatide at $297/mo produces substantially better outcomes for most patients. Phentermine's advantage remains its price point and no-injection oral convenience. Also read: Qsymia vs phentermine, phentermine vs semaglutide, full semaglutide vs phentermine comparison.